Physician Profile

L. Kristin Newby, MD

Education:
Medical School:
Indiana University School of Medicine, MD, 1987

Intership/Residency:
Duke University Medical Center, North Carolina, Internal Medicine, 1987-1990

Fellowship:
Duke University Medical Center, North Carolina, Cardiology, 1990-1993

Clinical Interests/Specialties:
General noninvasive and critical care cardiology including acute chest pain, acute and chronic coronary artery disease, heart failure, outpatient consultative cardiology

Research:
General Focus: Clinical investigation of the process and treatment of acute and chronic coronary artery disease and systems issues for delivery of care to patients with these illnesses. Particular interests include management of patients with chest pain and unstable angina, evaluation of the use of biochemical markers other than CK-MB for diagnosis and risk stratification in these patients, issues related to coronary artery disease in women, and systems issues regarding optimizing the process of delivery of care to patients with acute and chronic coronary artery disease. Finally, I have a strong interest in defining the genetic contribution to development of coronary artery disease.

Clinical Trials: My efforts are focused in 2 general areas: 1) diagnosis and risk stratification of patients with chest pain and acute coronary syndromes and 2) secondary prevention of coronary artery disease. In collaborative efforts, we are currently evaluating, in the multi-center CHECKMATE trial, the role of point-of-care biochemical markers in diagnosis and risk stratification of a low-moderate risk population of Chest Pain Unit patients. Through substudies of 2 major international trials we are investigating 1) the prognostic importance of cardiac troponins in patients post-percutaneous intervention and 2) the relative effect of early platelet GP IIb/IIIa antagonist therapy in troponin-positive versus -negative patients. As the Co-PI for HERS, we continue to investigate the surprising results of hormone replacement therapy for secondary prevention of coronary disease in post-menopausal women and are now pursuing the HERS II long-term follow-up. I am involved at both the site and coordinating center levels in multi-center international trials administration with the sibrafiban projects SYMPHONY, and 2nd SYMPHONY which evaluate the secondary prevention role of sibrafiban, an oral platelet GP IIb/IIIa receptor antagonist, in patients post-acute coronary syndromes. Finally, I am PI for the Duke site in GeneQuest, a study that is attempting to identify a gene/s linked to premature atherosclerosis.

Key words: coronary artery disease, acute myocardial infarction, unstable angina, chest pain, women, biochemical markers, risk stratification, genetics

Hospital Affiliations:
Duke University Medical Center